(RTTNews) - Hoth Therapeutics, Inc. (HOTH) Tuesday announced positive preclinical results for HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST). GIST is a rare but ...

Hoth Therapeutics announces positive preclinical results for HT-KIT in aggressive cancer gastrointestinal stromal tumours: New York Wednesday, March 19, 2025, 18:00 Hrs [IST] Hoth ...

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...

Researchers at the University of Pittsburgh have found special high-risk cells in the fallopian tubes that may trigger ...

Hoth Therapeutics (HOTH) announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted ...

High-grade glioma, a difficult-to-treat and aggressive form of pediatric and adult brain cancer, responded to FDA-approved avapritinib. | Drug Discovery And Development ...

We recently published a list of 10 Stocks Insiders Are Selling In March. In this article, we are going to take a look at ...

Women with polycystic ovary syndrome (PCOS) find it harder to get pregnant, have more frequent miscarriages and have a higher ...

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics , a leader in the ...

which is already approved by the United States Food and Drug Administration to treat gastrointestinal stromal tumors ... Genetic Mutations Linked to Toxin Exposure Found in Firefighters' Brain ...

Scientists have uncovered a hidden driver of ovarian cancer—high-risk mesenchymal stem cells lurking in the fallopian tubes.

Researchers at the University of Pittsburgh have identified a novel trigger of a deadly form of ovarian cancer: a subset of ...